{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7"},{"groupId":"OG001","value":"44.1"},{"groupId":"OG002","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"93"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"MR1 was defined as percentage of participants achieving a ratio of \\<=10% Breakpoint Cluster Region-Abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (i.e., participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug.","reportingStatus":"POSTED","timeFrame":"3 months after the first dose of study treatment","title":"Percentage of Participants With Molecular Response 1 (MR1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}